Hoth Therapeutics Starts Preclinical Study For Its Alzheimer's Candidate

by Vandana Singh, Benzinga Editor
August 2, 2021 11:11 AM | 1 min read |
  • Hoth Therapeutics Inc HOTH has initiated its preclinical study utilizing Hoth's HT-ALZ in an animal model.
  • The study aims to determine the effects of HT-ALZ on behavioral and pathological markers of Alzheimer's disease and determine if HT-ALZ can improve learning and memory in an animal model of Alzheimer's disease. 
  • Hoth study will also determine if the behavior is improved utilizing HT-ALZ in blocking NK-1Rs. 
  • The designed studies are taking place under a Scientific Research Agreement entered by Hoth in June 2021.
  • Price Action: HOTH shares are up 3.87% at $1.34 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In:
BiotechNewsPenny StocksHealth CareGeneralAlzheimer's diseaseBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved